Biocept appoints Dr Michael Dugan as chief medical officer and medical director

Biocept Inc (NASDAQ:BIOC), a leading commercial provider of liquid biopsy tests, announced Monday the appointment of Dr Michael Dugan as its chief medical officer and medical director.  Dr Dugan has served in leading medical positions at Exact Sciences, Quest Diagnostics, and Roche Molecular Systems, Biocept noted.  At Biocept he will be responsible for medical policy decision-making and the operations of the company’s CLIA-certified, CAP-accredited, high-complexity molecular laboratory in San Diego. READ: Biocept expands availability of its COVID-19 testing services via large healthcare network “Mike is highly respected in the molecular diagnostics industry, and we are thrilled to welcome him to our executive team,” said Biocept CEO Michael Nall in a statement. “Mike is particularly known within our industry for his outstanding leadership capability and commercial vision. He has proven experience in developing clinical strategies and designing and overseeing studies that validate clinical utility.” Dr Dugan brings to Biocept more than 25 years of industry experience, most recently as president and CEO of MCDXI Medical Diagnostics International, a professional advisory group practice where he consulted with biotechnology companies in oncology diagnostics, medical device development, and clinically related software applications.  Before that, he was senior medical advisor and chief medical officer at Clinical Genomics Inc, a biotechnology company developing an innovative product for colorectal cancer recurrence monitoring using circulating tumor DNA (ctDNA) in plasma.  He has also been senior vice president of Clinical Development and Medical Affairs at Exact Sciences Corporation, medical director at Quest Diagnostics Nichols Institute (and Specialty Laboratories which they acquired), chief medical officer at bioTheranostics, vice president and chief medical officer at Roche Molecular Systems Inc, and vice president of Pathology Services at Genzyme Genetics (acquired by LabCorp). “I’m excited to join Biocept to further develop and commercialize leading-edge assays that profile and monitor molecular signatures of cancer to help improve patient treatment choices and outcomes,” Dr Dugan said.  Contact the author: patrick@proactiveinvestors.com Follow him on Twitter @PatrickMGraham